(Q35016421)

5 August 2017

1 reference

title

The cladribine conundrum: deciphering the drug's mechanism of action (English)

1 reference

5 August 2017

Patricia Hentosh

1

1 reference

5 August 2017

Dennis M Peffley

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

5 August 2017

published in

1 reference

5 August 2017

volume

6

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

75-81

1 reference

Cladribine: from the bench to the bedside--focus on hairy cell leukemia

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Identification and development of new therapeutics for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Cladribine in aggressive forms of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Purine nucleoside analogues in the treatment of myleoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

RNAi depletion of deoxycytidine and deoxyguanosine kinase in human leukemic CEM cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Pharmacological basis for cladribine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

The antileukemia drug 2-chloro-2'-deoxyadenosine: an intrinsic transcriptional antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Preferential DNA repair of an active gene in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Cladribine: not just another purine analogue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Cladribine (2-chlorodeoxyadenosine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

2-Chloro-2'-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Cellular stress response and apoptosis in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Caspase inhibition switches doxorubicin-induced apoptosis to senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Identification of Atg5-dependent transcriptional changes and increases in mitochondrial mass in Atg5-deficient T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Platonin induces autophagy-associated cell death in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Brevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393745

10.1517/17425250903393745

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference